Stocktoria
AVITA Medical, Inc. RCEL
AVITA Medical, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $71.6M | $64.3M | $50.1M | $34.4M | $29.2M | $14.3M | $5.5M |
| Gross profit | $58.8M | $55.2M | $42.4M | $28.4M | $23.3M | $11.3M | $4.2M |
| R&D expense | $20.8M | $20.4M | $20.8M | $13.9M | $14.8M | $9.2M | $8.0M |
| Operating income | -$42.5M | -$56.6M | -$42.7M | -$27.5M | -$26.5M | -$42.7M | -$25.5M |
| Interest expense | $5.0M | $5.4M | $1.1M | $16,000 | $22,000 | $33,000 | $27,000 |
| Income tax | $11,000 | $54,000 | $66,000 | $36,000 | $38,000 | $4,000 | -$121,000 |
| Net income | -$48.6M | -$61.8M | -$35.4M | -$26.7M | -$26.6M | -$42.0M | -$25.1M |
| EPS (diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | $1.17 | $2.07 | $1.56 |
| Operating cash flow | -$31.2M | -$48.9M | -$38.0M | -$19.1M | -$25.9M | -$22.7M | -$19.2M |
| Free cash flow | -$32.2M | -$58.1M | -$39.4M | -$19.5M | -$26.8M | -$23.3M | -$20.3M |
| Cash & equivalents | $10.2M | $14.1M | $22.1M | $18.2M | $110.7M | $73.6M | $20.2M |
| Inventory | $6.9M | $7.3M | $5.6M | $2.1M | $1.6M | $1.1M | $742,000 |
| Total assets | $56.4M | $79.7M | $111.6M | $98.3M | $125.5M | $82.5M | $25.8M |
| Total liabilities | $73.0M | $75.0M | $61.9M | $13.0M | $9.8M | $10.1M | $5.0M |
| Shareholders' equity | -$16.6M | $4.5M | $49.1M | $84.7M | $115.7M | $72.4M | $20.8M |
Growth · year-over-year · Revenue CAGR 53.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +11.5% | +28.1% | +45.7% | +17.8% | +104.9% | +160.6% | — |
| EPS growth | — | — | -230.8% | -8.5% | -43.5% | +32.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.